Sol J. Barer
Independent Chairman of the BoardDr. Sol J. Barer, Ph.D., is a Director at Zephyr AI, Inc. He is an Independent Chairman of the board at NexImmune, Inc. since November 2019 and is its Independent Director. He serves as Senior Advisor at Red Cell Management, LLC (formerly known as Red Cell Partners, LLC). He serves as Director and Advisor To The Board of Directors of Cornerstone Pharmaceuticals, Inc. (formerly known as Rafael Pharmaceuticals, Inc.). Dr. Barer serves as Special Advisor and Strategic Advisory Board at Avalo Therapeutics, Inc. (formerly known as Cerecor Inc.) since June 15, 2021. Dr. Barer has served as Chairman of the Hackensack Meridian Health Center for Discovery & Innovation since June 2018 and as a member of Barer & Son Capital since 2017. Dr. Barer also serves on the boards of directors of several public companies, including ContraFect Corporation as lead Director. Dr. Barer serves as Board Advisor at WaveGuide Corporation. Dr. Barer served as Chairman of the Board at Avalo Therapeutics, Inc. (formerly known as Cerecor Inc.) since June 2020 until June 15, 2021 and also served as its Director since February 3, 2020 until June 15, 2021. Dr. Barer served as Executive Chairman at Avalo Therapeutics, Inc. (formerly known as Cerecor Inc.) since April 24, 2020 until June 2020. Dr. Barer served as Special Advisor to Chairman at Immunomedics, Inc. since April 22, 2016. Dr. Barer is the Managing Partner at SJ Barer Consulting. He served as an Advisor of DelMar Pharmaceuticals, Inc. Dr. Barer is a Founder of MIG. He is a Venture Advisor at Israel Biotech Fund. Dr. Barer serves as a Consultant of Efung Capital. He is a biotechnology industry veteran and serves as a Senior Advisor to a number of other biotechnology companies. Dr. Barer served as a Secretary of BioNJ Inc. He founded Celgene Corporation and served as its Chairman from January 2011 to June 2011, Executive Chairman from June 2010 to January 2011, Chief Executive Officer from May 1, 2006 to June 16, 2010, President from October 1993 to May 1, 2006, Chief Operating Officer from March 1994 to May 1, 2006 and Vice President of Technology from September 1987 to October 1990. Dr. Barer joined Celgene Corporation in 1987 and served as its Executive Director from March 1994 to December 31, 2010. He worked with Celanese Corporation, where he served as Senior Vice President of Science and Technology and served as its Vice President and General Manager of Chiral Products from October 1990 to October 1993. He joined the Celanese Research Company in 1974 and formed the biotechnology group that was subsequently spun out to form Celgene. From 1987 to 2011, he served in top leadership roles at Celgene Corporation. He was a founder of the biotechnology group at Celanese Corporation, which was later spun off as Celgene. Dr. Barer has been the Chairman of the Board at Teva Pharmaceutical Industries Limited since February 6, 2017 and as its Director since January 1, 2015. Dr. Barer serves as the Chairman of the Board at Semorex Inc. He serves as the Chairman of Centrexion Therapeutics Corporation (formerly known as Centrexion Corp). He had been the Chairman at Aevi Genomic Medicine, Inc., (alternate name, Medgenics, Inc.) since July 2012 until February 3, 2020 and served as its Director until February 3, 2020. Dr. Barer served as Director at PDS Biotechnology Corporation. He served as the Chairman of InspireMD, Inc. from November 16, 2011 to June 2, 2017. Dr. Barer, Chairman of the Board of Teva Pharmaceuticals and Board Member of 3DBiotherapeutics. Dr. Barer is also the Founding Board Member of the Barer Institute, a collaborative cancer drug development initiative of Rafael Holdings, Inc. Dr. Barer served as the Chairman of Avalo Therapeutics, Inc. (formerly known as Cerecor Inc.) from January 10, 2012 to April 23, 2015. He served as Chairman of Scientific Advisory Board at MYOS Corporation (now MYOS RENS Technology Inc.) since June 27, 2012. Dr. Barer served as Chairman of ContraFect Corporation since February 2012 until May 20, 2015. He served as the Chairman and Director of Restorgenex Corporation from November 1, 2013 to January 8, 2016. He served as Independent Director of Amicus Therapeutics, Inc. from January 2009 to February 9, 2017. He has been Member of Strategic Advisory Board at SpendSmart Networks, Inc. since September 2012. He served as an Independent Director of InspireMD, Inc. from July 11, 2011 to June 2, 2017. He serves as a Director at 3D Bio Holdings, Inc. He has been Independent Director of ContraFect Corporation since February 24, 2011 and has been its Lead Director since May 20, 2015. Dr. Barer serves as a Director of Centrexion Therapeutics Corporation (formerly known as Centrexion Corp) and Semerex, Inc. He serves as Member of Scientific Advisory Board at MYOS Corp. Dr. Barer serves on the editorial board of Biocatalysis. He served as Director of Celgene Corporation from January 1, 2011 to June 15, 2011. He served as Director of Aegerion Pharmaceuticals, Inc. from May 1, 2011 to November 29, 2016. Dr. Barer served as Director of Avalo Therapeutics, Inc. (formerly known as Cerecor Inc.) until April 23, 2015. He served as a Member of Scientific and Clinical Advisory Board at Heat Biologics, Inc. since June 2011 and served as its Member of Scientific Advisory Board. Dr. Barer served as a Director of Nobex Inc. and Nobex Corporation. He served as the Chairman of the Board of Trustees of BioNJ Inc. from 2010 to 2012. Dr. Barer serves as the Founding Chairman of the Rutgers Graduate School Dean's Advisory Council and the Rutgers Bioscience Commercialization Advisory Board. He serves on the New Jersey Commission of Science and Technology. He is a member of the Board of Directors for 3DBio Therapeutics. He served as Board of Trustees at Rutgers University until 2013. Dr. Barer serves on the Board of the Brooklyn College Foundation the Board of Trustees of Rutgers - The State University of New Jersey and the Board of the Tourette Syndrome Association. He served as Commissioner of the New Jersey Commission on Science and Technology. Dr. Barer holds a number of patents and publications. He received an LL.D. (Honorary) in Law from the Rabbinical College of America in 2018. He obtained his Ph.D. in Organic and Physical Chemistry from Rutgers University in 1974. Dr. Barer holds a BS in Chemistry from Brooklyn College of the City University of New York in 1968. Dr. Barer had been the Chairman at Edge Therapeutics, Inc. since 2011 until 2019. Dr. Barer had been Director of Edge Therapeutics, Inc. from September 1, 2011.
Positions
- Company NameTeva Pharmaceutical Industries LimitedStock CodeTEVAPositionIndependent Chairman of the BoardColleagues
- RDRichard D. FrancisPresident, CEO & Director
- SJSol J. BarerIndependent Chairman of the Board
- ESEliyahu Sharon KalifExecutive VP & CFO
- CFChristine FoxExecutive VP of US Commercial & Head of Innovative Franchise
- ELEvan LippmanExecutive Vice President of Business Development
- MSMatthew ShieldsExecutive Vice President of Global Operations
- RARosemary A. CraneIndependent Director
- GMGerald M. LiebermanIndependent Director
- RARoberto Agostino MignoneIndependent Director
- Company NameContraFect CorporationStock CodeCFRXQPositionLead Independent DirectorColleagues
- MMMichael MessingerCEO, President, CFO & Principal Accounting Officer
- RJRoger James PomerantzChairman
- NBNatalie BogdanosGeneral Counsel, Corporate Secretary & Data Protection Officer
- MSMatthew SalamoneVice President of Human Resources
- GWGary WoodnuttSenior Vice President of Translational Sciences & Preclinical Development
- WGWilliam Garrett NicholsInterim Chief Medical Officer
- SCSteven C. GilmanVice Chairman
- VAVincent A. FischettiChairman of Scientific Advisory Board
- DNDavid N. LowIndependent Director
